Reports Q3 revenue $700M, consensus $663.51M. “Our third quarter results reflect continued execution and meaningful progress against our strategic and financial priorities,” said Brian J. Blaser, President and Chief Executive Officer of QuidelOrtho (QDEL). “Through disciplined execution and focused investments in our highest-growth areas, we are expanding margins and accelerating innovation-most recently with the addition of high-sensitivity Troponin on our VITROS platform. Backed by a broad portfolio, global reach, and operational focus, we believe we are well positioned to deliver sustainable growth and long-term value for our shareholders.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QDEL:
- QuidelOrtho receives FDA 510(k) clearance for VITROS hs Troponin I Assay
- Is QDEL a Buy, Before Earnings?
- QuidelOrtho Hold Rating: Impact of Debt Refinancing and Chinese Market Risks
- QuidelOrtho downgraded to Neutral from Buy at Citi
- QuidelOrtho announces availability of QUICKVUE Influenza + SARS Test